HDAC9 and neoplasm: Reintroduction of PTEN in tumor cells increased their therapeutic sensitivity to PDGFR inhibitors, and the combination of histone deacetylase (HDAC) and PDGFR inhibitors effectively reduced the growth and invasion of chordoma cells, irrespective of PTEN status (69).